A small but growing body of evidence suggests that a minimally invasive surgical procedure—called lymphovenous anastomosis (LVA)—might be an effective treatment for Alzheimer's disease, according to a special article in Plastic and Reconstructive Surgery.
Sometimes called lymphovenous bypass, LVA is a relatively simple surgical procedure in which lymphatic vessels are connected to neighboring blood vessels to improve lymphatic flow. The concept of LVA is not new; it is commonly performed to relieve obstructed lymph flow causing severe swelling, often as a complication of cancer treatment.
In recent years, studies have suggested that impaired lymph flow in the brain—called "glymphatic" flow because it is regulated by brain cells called glia—may contribute to Alzheimer’s-related abnormalities, including amyloid-beta plaques and deposits of tau protein. Damage to glymphatic flow may lead to reduced clearance of neurotoxins, particularly during sleep. Lifestyle changes and medications have been suggested to enhance brain lymphatic flow, but with limited effectiveness.
By creating a direct connection between lymphatic vessels and veins, LVA bypasses blocked or dysfunctional lymphatic pathways, providing continuous, passive improvement in glymphatic flow.
Initial studies have supported the benefits of LVA surgery in patients with AD, with improved cognitive test scores and sometimes dramatic gains in mental and physical functioning. Some studies have linked these clinical improvements to evidence of increased lymphatic flow.
“LVA represents a novel therapeutic strategy that may complement existing treatments, offering new hope for addressing the pathophysiology of AD,” the paper concludes. “Through collaborative, long-term clinical trials, LVA may emerge not only as an adjunct to current [Alzheimer’s disease] therapies but also as a potential treatment avenue for other neurodegenerative diseases."
Data from Wolters Kluwer Health